These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38472557)

  • 1. A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patients.
    Pal R; Choudhury T; Ghosh M; Vernakar M; Nath P; Nasare VD
    Clin Transl Oncol; 2024 Jul; 26(7):1716-1724. PubMed ID: 38472557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
    Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
    PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.
    Zuberi M; Khan I; Gandhi G; Ray PC; Saxena A
    Tumour Biol; 2016 Aug; 37(8):11259-66. PubMed ID: 26951510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating miRNA-199a and miRNA-122 Levels as Potential Diagnostic and Prognostic Biomarkers for Hepatocellular Carcinoma.
    Wu J; Wu Y; Luo Y; Li X; Lin N; Yang X; Lin Y; Chen M
    Ann Clin Lab Sci; 2020 Mar; 50(2):219-227. PubMed ID: 32366560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
    Robelin P; Tod M; Colomban O; Lachuer J; Ray-Coquard I; Rauglaudre G; Joly F; Chevalier-Place A; Combe P; Lortholary A; Hamizi S; Raban N; Ferron G; Meunier J; Berton-Rigaud D; Alexandre J; Kaminsky MC; Dubot C; Leary A; Malaurie E; You B
    Gynecol Oncol; 2020 Oct; 159(1):256-263. PubMed ID: 32712155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer.
    Zheng H; Zhang L; Zhao Y; Yang D; Song F; Wen Y; Hao Q; Hu Z; Zhang W; Chen K
    PLoS One; 2013; 8(11):e77853. PubMed ID: 24223734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low serum exosomal miR-484 expression predicts unfavorable prognosis in ovarian cancer.
    Zhang W; Su X; Li S; Liu Z; Wang Q; Zeng H
    Cancer Biomark; 2020; 27(4):485-491. PubMed ID: 32065786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
    Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
    Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study.
    Lou E; Vogel RI; Hoostal S; Wong P; Grad A; Monu M; Łukaszewski T; Deshpande J; Dickson EL; Klein M; Linden MA; Subramanian S; Teoh D; Geller MA
    Oncologist; 2019 Nov; 24(11):1422-e1013. PubMed ID: 31346130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
    Gasparini P; Cascione L; Fassan M; Lovat F; Guler G; Balci S; Irkkan C; Morrison C; Croce CM; Shapiro CL; Huebner K
    Oncotarget; 2014 Mar; 5(5):1174-84. PubMed ID: 24632568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.
    Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J
    EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer.
    Zuberi M; Khan I; Mir R; Gandhi G; Ray PC; Saxena A
    PLoS One; 2016; 11(4):e0153902. PubMed ID: 27092777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
    Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Promising Signatures of Circulating microRNA-145 in Epithelial Ovarian Cancer Patients.
    Zuberi M; Mir R; Khan I; Javid J; Guru SA; Bhat M; Sumi MP; Ahmad I; Masroor M; Yadav P; Vishnubhatla S; Saxena A
    Microrna; 2020; 9(1):49-57. PubMed ID: 30799804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
    Liu B; Su F; Chen M; Li Y; Qi X; Xiao J; Li X; Liu X; Liang W; Zhang Y; Zhang J
    Hum Pathol; 2017 Jun; 64():44-52. PubMed ID: 28412211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
    Wang WT; Guo CQ; Cui GH; Zhao S
    World J Gastroenterol; 2019 Oct; 25(37):5604-5618. PubMed ID: 31602161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a 7-microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection.
    Zhang H; Zou X; Wu L; Zhang S; Wang T; Liu P; Zhu W; Zhu J
    Cancer Med; 2020 Feb; 9(3):1230-1241. PubMed ID: 31856390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study.
    Panoutsopoulou K; Avgeris M; Mavridis K; Dreyer T; Dorn J; Obermayr E; Reinthaller A; Michaelidou K; Mahner S; Vergote I; Vanderstichele A; Braicu I; Sehouli J; Zeillinger R; Magdolen V; Scorilas A
    Carcinogenesis; 2020 Jun; 41(4):442-451. PubMed ID: 31586203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.